Loading...

FHTX FOGHORN THERAPEUTICS INC Investments/Divestments 8-K Filing

FGHR

FHTX

FOGHORN THERAPEUTICS INC

(FHTX)

2024 8-K

Management Change

Investor Presentation

Financial Update

Pipeline Updates

Investor Presentation

Financial Statements

Management Changes

Financial Statements

Clinical Trials

Investor Presentation

Stock Sale Amendment

Financial Results

Investor Presentation

Audit Committee Notice

Preliminary Results

Director Resignation

Product Discontinuation

Financial Results

Trial Announcement

Financial Results Announcement

Annual Meeting of Stockholders

Public Offering

Financial Results Announcement

Appointment of CFO

Conference Call and Webcast

Financial Results Announcement

Appointment of CFO

Press Release and Investor ...

Departure of Chief Financia...

Financial Results Announcement

Termination of Agreement

Management Changes

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Update on FHD-609 Program

Financial Results and Bylaw...

Press Release and Investor ...

External Links:

Foghorn Therapeutics Inc. issued a press release announcing that Eli Lilly and Company has selected FHD-909 for clinical development in the treatment of BRG1 mutated non-small cell lung cancer.

AI Assistant

FOGHORN THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.